The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients
复制标题
DOI：
10.1007/s00280-019-03895-2
复制
发表时间：
2019-09-01
影响因子：
3
通讯作者：
Saruta, Masayuki
中科院分区：
文献类型：
--
作者：
Ishimoto, Utako;Kinoshita, Akiyoshi;Saruta, Masayuki
目的 与年轻患者相比，评估白蛋白结合型紫杉醇 (nab-P) 加吉西他滨 (GEM) 对 75 岁以上老年不可切除胰腺癌 (PC) 患者的疗效和安全性。方法回顾性分析27例接受nab-P联合GEM一线化疗的不可切除PC患者的资料。根据纳入时的年龄将患者分为两组：老年组（9名患者> = 75岁）和年轻组（18名患者= 6.5）在多变量分析中发现是不良预后因素。最常见的> = 3级AE是中性粒细胞减少症（两组均为44％）。两组之间所有AE的频率没有观察到显着差异。结论Nab-P加GEM似乎有效且有效对于≥ 75 岁且不可切除 PC 的老年患者耐受性良好。
Purpose To evaluate the efficacy and safety of nab paclitaxel (nab-P) plus gemcitabine (GEM) in elderly patients >= 75 years old with unresectable pancreatic cancer (PC) compared with younger patients. Methods The data of 27 unresectable PC patients treated with nab-P plus GEM as first-line chemotherapy were retrospectively analyzed. The patients were divided into two groups according to their age at inclusion: an elderly group (9 patients >= 75 years old) and a younger group (18 patients = 6.5 were found to be poor prognostic factors in a multivariate analysis. The most common grade >= 3 AE was neutropenia (44% in both groups). No significant differences in the frequency of all AEs were observed between the two groups. Conclusions Nab-P plus GEM appears effective and well-tolerated for elderly patients >= 75 years old with unresectable PC.